Skip to content
Open access

Real-world effectiveness of first-line chemoimmunotherapy versus chemotherapy in older adults with extensive-stage small cell lung cancer: an inverse probability treatment weighted analysis.

Oct 2026 · Future Oncology · pp. 1-12 · 0 citations · 29 references
Medicine

TL;DR

Comparison evidence of improved survival in association with ICI-chemo compared with chemo in older adults with ES-SCLC is provided, providing comparative evidence of improved survival in association with ICI-chemo.

Abstract

Aims

First-line chemoimmunotherapy (ICI-chemo) has become the standard of care for extensive-stage small cell lung cancer (ES-SCLC). However, older adults are underrepresented in pivotal trials due to strict inclusion criteria that limit participation to highly selected, fit patients. Given the limited real-world comparative data, this study aimed to determine whether older adults with ES-SCLC derive greater benefit from ICI-chemo compared with chemotherapy (chemo) alone. PATIENTS AND

Methods

We conducted a single-center retrospective cohort study including ES-SCLC patients aged 65 years or older who started first-line ICI-chemo or chemo between January 2020 and July 2024. Inverse probability of treatment weighting (IPTW) was used to adjust for baseline confounding. The main outcome was overall survival (OS) in the IPTW population.

Results

In the IPTW population, median OS was significantly longer in the ICI-chemo group (14.95 months; 95% CI, 12.94-19.91) compared with chemo (10.28 months; 95% CI, 8.11-13.17; HR, 0.66; 95% CI, 0.48-0.91; p = 0.011). Multivariable analysis confirmed that ICI-chemo exposure was independently associated with improved OS (HR, 0.608; 95% CI, 0.440-0.841; p = 0.003).

Conclusions

Our findings provide comparative evidence of improved survival in association with ICI-chemo compared with chemo in older adults with ES-SCLC.

Read PDF

Similar papers

Open access Nov 2026

Real-world treatment patterns and survival outcomes in extensive-stage small cell lung cancer across first-line induction and maintenance therapy

Abstract Background Platinum-etoposide (PE) chemotherapy combined with a programmed cell death ligand 1 (PD-L1) inhibitor is the current first-line (1L) standard of care for extensive-stage small cell lung cancer (ES-SCLC). Real-world evidence describing outcomes across induction and maintenance phases remains limited....

Yi-Shao Liu, P. Desai, H. Khurshid et al. · 0 citations
Open access Nov 2026

Comparison of First-Line Pembrolizumab Monotherapy Versus Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Multicenter Real-World Study from Turkey

Background and Objectives: This study aimed to compare the real-world outcomes of first-line pembrolizumab monotherapy (Mono-IO) versus pembrolizumab plus platinum-based chemotherapy (IO + ChT) in patients with metastatic non-small cell lung cancer (mNSCLC) and a PD-L1 tumor proportion score (TPS) ≥ 50%. Materials and...

Ozde Melisa Celayir, B. Köylü, Harun Muğlu et al. · 0 citations
Open access Oct 2026

Real-World Comparative Survival Outcomes of First-Line Serplulimab Plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer: A Single-Center Retrospective Cohort Study

Background Extensive-stage small-cell lung cancer (ES-SCLC) remains an aggressive malignancy with poor survival despite platinum-etoposide chemotherapy. Although serplulimab plus chemotherapy has demonstrated a survival benefit in randomized trials, comparative real-world evidence remains limited. We therefore evaluate...

Y. Jing, Miao Li, Song-Xiang Li et al. · 0 citations
Review Open access Sep 2026

Efficacy and safety of first-line immunotherapy-related induction and maintenance therapy for extensive-stage small cell lung cancer: a systematic review and Bayesian network meta-analysis

Background Extensive-stage small cell lung cancer (ES-SCLC) is highly aggressive with dismal prognosis, and platinum monochemotherapy offers modest long-term survival. Multiple first-line regimens integrating immunotherapy, anti-angiogenic agents and chemotherapy have been approved, yet direct head-to-head comparisons...

Hong-Jing Yu, Jun-Chen Liu, Dong-Sheng Zhang et al. · 0 citations
Open access Sep 2026

Greater survival benefits in small cell lung cancer patients: a real-world study with immune checkpoint inhibitors therapy

Real-world evidence is provided supporting the use of ICI-based therapy in SCLC, particularly in advanced-stage disease, but should be interpreted cautiously given the retrospective design and subgroup sample sizes.

Peng-Hu Gao, Hong-Bing Zhang, Ming-Hui Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.